Prevail Therapeutics (NASDAQ:PRVL) Upgraded at Zacks Investment Research

Prevail Therapeutics (NASDAQ:PRVL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Zacks.com reports. The firm presently has a $11.00 price objective on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 2.80% from the stock’s current price.

According to Zacks, “Prevail Therapeutics Inc. is a gene therapy company. It focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company’s product candidate consists of PR001, PR006 and PR004 which are in clinical stage. Prevail Therapeutics Inc. is based in New York. “

Several other brokerages have also recently issued reports on PRVL. Bank of America initiated coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued a “buy” rating and a $15.00 price target for the company. Cowen initiated coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued an “outperform” rating for the company. Morgan Stanley initiated coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued an “overweight” rating and a $20.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating on shares of Prevail Therapeutics in a research note on Wednesday, September 11th. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $16.50.

Shares of NASDAQ:PRVL traded down $0.21 during trading on Thursday, reaching $10.70. 59,508 shares of the stock were exchanged, compared to its average volume of 108,077. Prevail Therapeutics has a 12 month low of $7.41 and a 12 month high of $16.90. The company’s 50-day moving average is $11.24. The company has a quick ratio of 26.94, a current ratio of 26.94 and a debt-to-equity ratio of 0.04.

Prevail Therapeutics (NASDAQ:PRVL) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.66. Equities research analysts expect that Prevail Therapeutics will post -2.53 earnings per share for the current year.

Several hedge funds have recently modified their holdings of the stock. Blackstone Group Inc bought a new stake in shares of Prevail Therapeutics in the second quarter valued at approximately $66,000. Point72 Hong Kong Ltd bought a new stake in Prevail Therapeutics during the second quarter worth $106,000. Morgan Stanley bought a new stake in Prevail Therapeutics during the second quarter worth $166,000. Northern Trust Corp bought a new stake in Prevail Therapeutics during the second quarter worth $188,000. Finally, SG Americas Securities LLC bought a new stake in Prevail Therapeutics during the second quarter worth $194,000. Institutional investors and hedge funds own 77.49% of the company’s stock.

About Prevail Therapeutics

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Recommended Story: What is the Rule of 72?

Get a free copy of the Zacks research report on Prevail Therapeutics (PRVL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.